Researchers Develop 3D-Bioprinted Retinal Grafts
The two-year grant supports research into restoring vision for patients with degenerative retinal conditions.
Updated on Oct. 30, 2026 in Biotech
Live Poll
Should government funding prioritize the development of advanced 3D-bioprinting technologies for medical treatments?
Researchers at the Terasaki Institute for Biomedical Innovation have received an R56 grant from the National Eye Institute to develop 3D-bioprinted retinal grafts. This research-stage project aims to treat vision loss caused by age-related macular degeneration and retinitis pigmentosa.
Why it matters
The R56 award provides crucial funding to advance high-priority research, allowing the team to generate preliminary data for future R01 grant applications. This work explores whether specific graft architectures can improve the survival and integration of transplanted retinal cells.
The study utilizes Filamented Light 3D bioprinting to construct grafts from stem cell-derived photoreceptor precursors and supporting retinal cells. Success is measured by whether this engineered architecture enhances functional recovery in preclinical models.
The players
Dr. Johnson V. John
Lead researcher at the Terasaki Institute for Biomedical Innovation focused on 3D-bioprinted tissue engineering.
National Eye Institute
A federal research organization that funds vision science and clinical trials to address blinding eye diseases.
Terasaki Institute for Biomedical Innovation
A research entity specializing in biofabrication, lab-on-a-chip technologies, and tissue engineering.
The details
The team constructs these grafts by using specialized bioprinting that relies on light-based curing to position cells precisely. These engineered tissues integrate stem cell-derived photoreceptor precursors—specialized cells in the retina that convert light into nerve signals—alongside supporting retinal cells. This architectural approach is intended to provide a scaffold that mimics the native environment of the eye, facilitating better integration of the transplant.
Timeline
October 30, 2026: Official announcement of the R56 grant award.
1 to 2 years: Duration of the research support provided by the National Eye Institute.
The Tech Race
This project functions as a bridge toward the National Institutes of Health's R01 funding, which supports larger-scale, independent clinical investigations. It places the Terasaki Institute within a competitive field of labs racing to move stem cell-derived ocular therapies from research to preclinical verification.
This research is in the early stages and does not currently offer a clinical treatment option for patients. Future clinical applications depend on the project successfully passing preclinical validation and securing further institutional funding.
The takeaway
This grant enables the team to test whether structural engineering in bioprinted grafts can solve the historical difficulty of maintaining transplanted cell health. Readers should watch for future preliminary findings in the next two years that could pave the way for human clinical trials.
Further reading
For more on advancements in regenerative medicine, visit the Biotech section.
Source note: This article includes information reported by News-Medical.
Live Poll
Should government funding prioritize the development of advanced 3D-bioprinting technologies for medical treatments?
